AP -- Anadys Pharmaceuticals Inc. said Thursday that a potential hepatitis C drug met key goals in a midstage clinical trial. The company said 72 percent of patients taking ANA-598 had undetectable viral levels by the eighth week, compared with 38 percent taking placebo.
